Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patients |
| |
| Institution: | 1. Deparment of Hepatobiliary Medicine, Shanghai Public Health Clinical Center of Fudan University;2. Scientific Research Center, Shanghai Public Health Clinical Center of Fudan University;3. Department of Clinical Pathology, Shanghai Public Health Clinical Center of Fudan University;1. Servicio de Aparato Digestivo, Complejo Hospitalario de Navarra, Pamplona, Navarra, España;2. Servicio de Aparato Digestivo, Hospital García Orcoyen, Estella, Navarra, España;1. MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda;2. London School of Hygiene and Tropical Medicine, United Kingdom;1. Departamento de Cirugía General y del Aparato Digestivo, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Islas Canarias, España;2. Departamento de Radiodiagnóstico, Complejo Hospitalario Universitario Insular Materno-Infantil, Las Palmas de Gran Canaria, Islas Canarias, España;1. Consorci Hospital General y Universitari de Valencia, Valencia, España;2. Facultad de Ciencias de la Salud, Universidad CEU Cardenal Herrera, Alfara del Patriarca, Valencia, España;1. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran;2. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran;3. Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran;4. Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran |
| |
| Abstract: | ObjectiveTo evaluate the performance of the quantitative markers of hepatitis B core-related antigen (HBcrAg) and anti-hepatitis B core antigen antibodies HbcAb versus hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA (HBV DNA) in predicting liver fibrosis levels in chronic hepatitis B patients.MethodsTwo hundred and fifty hepatitis B e antigen (HBeAg)-positive and 245 HBeAg-negative patients were enrolled. With reference to the Scheuer standard, stage 2 or higher and stage 4 liver disease were defined as significant fibrosis and cirrhosis, respectively. A receiver operating characteristic (ROC) curve was used to evaluate the performance of the HBV markers investigated.ResultsThe areas under the ROC curves (AUCs) of HBcrAg in predicting significant fibrosis and cirrhosis in HBeAg-positive patients (0.577 and 0.700) were both close to those of HBsAg (0.617 and 0.762) (both P > 0.05). In HBeAg-negative patients (0.797 and 0.837), they were both significantly greater than those of HBV DNA (0.723 and 0.738) (P = 0.0090 and P = 0.0079). The AUCs of HBcAb in predicting significant fibrosis and cirrhosis in HBeAg-positive patients (0.640 and 0.665) were both close to those of HBsAg. In HBeAg-negative patients (0.570 and 0.621), they were both significantly less than those of HBcrAg (P < 0.0001 and P = 0.0001). Specificity in predicting significant fibrosis and sensitivity in predicting cirrhosis in HBeAg-positive patients, using a single cut-off of HBsAg ≤5,000 IU/ml, were 76.5% and 72.7%, respectively. In HBeAg-negative patients, using a single cut-off of HBcrAg >80kU/ml, they were 85.9% and 81.3%, respectively.ConclusionsHBsAg has good performance in predicting liver fibrosis levels in HBeAg-positive and HBeAg-negative patients, and HBcrAg has very good performance in predicting liver fibrosis levels in HBeAg-negative patients. |
| |
| Keywords: | Hepatitis B core-related antigen Anti-hepatitis B core antigen antibodies Hepatitis B surface antigen Virological marker Liver fibrosis Non-invasive diagnosis Antígeno relacionado con el núcleo de la hepatitis B Anticuerpos contra el antígeno del núcleo de la hepatitis B Antígeno de superficie de la hepatitis B Marcador virológico Fibrosis hepática Diagnóstico no invasivo |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
